Bridgeway Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Bridgeway Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.57M	Hold	299,641	–	–	0.03%	592
2025 Q4	$1.77M	Hold	299,641	–	–	0.04%	573
2025 Q3	$2.06M	Sell	299,641 -113,200	-27%	-$918K	0.04%	545
2025 Q2	$3.15M	Buy	412,841 +288,341	+232%	+$1.22M	0.07%	371
2025 Q1	$406K	Sell	124,500 -99,600	-44%	-$418K	0.01%	781
2024 Q4	$1.01M	Buy	224,100 +85,800	+62%	+$435K	0.02%	670
2024 Q3	$383K	Buy	138,300 +93,300	+207%	+$288K	0.01%	924
2024 Q2	$154K	Hold	45,000	–	–	﹤0.01%	1107
2024 Q1	$244K	Hold	45,000	–	–	0.01%	1071
2023 Q4	$244K	Buy	+45,000	New	+$212K	0.01%	1096

Other funds holding SGMT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bridgeway Capital Management's SGMT Position: Q1 2026 in Review

Bridgeway Capital Management held its Sagimet Biosciences (SGMT) position steady in Q1 2026 at 299,641 shares worth $1.57M. The position accounts for 0.03% of the portfolio, ranked #592.

Bridgeway Capital Management first reported a position in SGMT in Q4 2023 and has held it in 10 quarters since. The position peaked at $3.15M in Q2 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

Bridgeway Capital Management held 299,641 shares of Sagimet Biosciences worth $1.57M as of Q1 2026.
Bridgeway Capital Management left its Sagimet Biosciences share count unchanged in Q1 2026.
Sagimet Biosciences made up 0.03% of Bridgeway Capital Management's portfolio in Q1 2026, its #592 holding.
Bridgeway Capital Management first reported a position in Sagimet Biosciences in Q4 2023 and has held it in 10 quarters since.
Bridgeway Capital Management's Sagimet Biosciences position peaked at $3.15M in Q2 2025.
88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.